Neal S Kleiman, Nicolas M Van Mieghem, Michael J Reardon, Hemal Gada, Mubashir Mumtaz, Peter Skov Olsen, John Heiser, William Merhi, Stanley Chetcuti, G Michael Deeb, Atul Chawla, Bob Kiaii, Patrick Teefy, Michael W A Chu, Steven J Yakubov, Stephan Windecker, Andrew D Althouse, Suzanne J Baron
BACKGROUND: Symptomatic patients with severe aortic stenosis (AS) at high risk for surgical aortic valve replacement (SAVR) sustain comparable improvements in health status over 5 years after transcatheter aortic valve replacement (TAVR) or SAVR. Whether a similar long-term benefit is observed among intermediate-risk AS patients is unknown. OBJECTIVES: The purpose of this study was to assess health status outcomes through 5 years in intermediate risk patients treated with a self-expanding TAVR prosthesis or SAVR using data from the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial...
April 22, 2024: JACC. Cardiovascular Interventions